Specnova

01/27/2026

is almost here!

This years show, March 4 - 6, 2026, is right around the corner. We have some exciting news to share and would love to make time to catch up in person. Email us at [email protected] to set up a meeting.

📍 Booth # 4675
See you in Anaheim!

12/15/2025

Have you seen our recent clinical study on LipoVantage® Liposomal CoQ10?

Published in Frontiers in Nutrition, our new study shows that liposomal CoQ10 delivers significantly greater plasma exposure than conventional CoQ10.

Because CoQ10 is fat-soluble, it has traditionally needed to be taken with food to support absorption. This study showed that LipoVantage® liposomal CoQ10 eliminates that dependency, allowing CoQ10 to be effectively absorbed even when taken on an empty stomach, adding flexibility and ease for everyday use.

Why does improved bioavailability matter?
Enhanced absorption can:
• help achieve meaningful levels at lower doses
• benefit individuals with compromised fat digestion or absorption
• accelerate early exposure before longer-term benefits are realized

The takeaway: how an ingredient is delivered can be just as important as the ingredient itself.

Read more about the study here: https://specnova.com/studies/lipovantage-enhanced-coq10-absorption/

11/19/2025

A big thank you to Devon Gholam, Ph.D. and SupplySide for writing about the results from our most recent clinical study, “Effects of Tart Cherry Extract Supplementation on Plasma Urate and C-Reactive Protein Levels in Healthy Adults: A Randomized Controlled Trial”.

We are proud to see our NordicCherry® Tart Cherry Extract being highlighted for its real-world relevance. Thank you for covering the science and telling the story in a way the entire nutraceutical community can appreciate.

We’re excited to continue delivering performance-driven, science-based solutions and to collaborate with partners who value innovation, transparency, and efficacy. Here’s to more credible research, meaningful insights and meaningful impact!

European tart cherry extract demonstrated significant reductions in inflammation markers and uric acid levels in a 28-day clinical trial